Aida Pharmaceuticals (AIDA) Stock Analysis & Winston Score

Aida Pharmaceuticals is a small specialty pharmaceutical company that develops and sells prescription drugs. The company focuses on specialty and generic medications, selling primarily to pharmacies, hospitals, and healthcare providers. It operates in the broader drug manufacturing industry, which includes both branded specialty treatments and lower-cost generic alternatives.

The company earns revenue by selling its pharmaceutical products directly into the healthcare supply chain. With a market cap near zero, Aida is a very small player competing against much larger generic and specialty drug manufacturers. Its 50% gross margin suggests some pricing power, possibly from a niche product or limited competition in a specific drug category. The main risk for a company this size is its dependence on a small number of products — if a key drug loses exclusivity, faces a safety issue, or gets undercut by a competitor, revenue could drop sharply.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+61.2% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+300.0% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

75.4%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~5 years

$8M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

$8M cash & investments at current burn rate

Revenue accelerating

Aida Pharmaceuticals grew revenue 61% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

58.3%

Premium pricing power — 58.3% gross margin

Operating Margin

21.3%

Excellent — 21.3% operating margin

ROCE

5.0%

Weak — 5.0% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+40.9%

Fast-growing sales (40.9% YoY)

EPS YoY

-443.4%

Earnings shrinking (-443.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

2.2%

Thin free cash flow (2.2%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

4.49

Heavy debt load (4.49)

Interest Cover

4.79x

Adequate interest coverage (4.8x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

0.0x

no trend

Attractive valuation — P/E 0.0

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial